Reviewed listing: NASDAQ:QTTB · Analysis dated Oct 22, 2026
It has not been confirmed whether the basis of this analysis still holds today. Read it as a dated earlier assessment; it does not establish a current buying opportunity.
How does the company make money?
Q32 develops drugs for immune system disorders. Its focus is bempikibart for severe alopecia areata. It does not yet have an approved product of its own for sale.
What supports the business?
The small study to date provides an efficacy signal. In addition, the July capital raise brought in 187.6 million USD net and improves funding for the next stages of development.
What could improve?
If larger controlled studies confirm the results and approval is achieved, Bempikibart could reach a market of its own. Observations after treatment ended are interesting, but are not yet reliable evidence of long-term effects.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
At 8.67 USD, the stock should not be considered cheap solely because of its large cash balance. Pre-funded warrants substantially increase the economic share count; research consumes cash. The model range is too uncertain to set a firm price limit.
What is the main risk?
The available data comes from a small open-label study without a suitable control group. A negative later result could largely erase the development value; further financing could dilute the ownership of today's shareholders.
What is the overall assessment?
Watch: Q32 has early clinical signals and more cash following its capital raise. Whether this leads to an effective, approved, and commercially successful drug remains open; a reliably attractive share price has not been established.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign in